Core Viewpoint - The announcement highlights the registration of the Iberis RDN system in New Zealand, marking a significant milestone for the company in the renal denervation market [1] Company Summary - The Iberis RDN system, developed by the company's subsidiary Shanghai Antong Medical Technology Co., Ltd., has received approval from New Zealand's Medicines and Medical Devices Safety Authority (Medsafe) [1] - The Iberis RDN system is the only renal denervation product globally approved for both transradial access (TRA) and transfemoral access (TFA) methods [1] - The TRA method enhances the safety, efficacy, and cost-effectiveness of renal denervation procedures [1] - The company's ultimate goal is to provide outpatient renal denervation surgeries for patients worldwide [1] - The Iberis RDN system received CE marking in Europe in 2016, indicating its compliance with European health, safety, and environmental protection standards [1]
百心安-B(02185)：IBERIS® RDN系统在新西兰注册